OptiNose joins the biotech IPO fiesta, raises $120M in upsized offering
A month after bagging an FDA approval of its drug/device for nasal polyps, OptiNose has taken advantage of a red-hot biotech IPO market to raise …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
